Searched for
ELI LILLY ACQUISITION
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Eli Lilly to buy Ajax Therapeutics for up to $2.3 billionEli Lilly is set to acquire Ajax Therapeutics for a substantial sum. This move aims to develop a new oral treatment for myelofibrosis, a ra...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Eli Lilly bets on next-generation cell therapy with $2.4 billion deal for OrnaEli Lilly will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients' own cells to gen...
- European stocks rise as Novo Nordisk lifts healthcare on Wegovy dataShares of Novo Nordisk, the fourth-largest healthcare company on the STOXX index, climbed 3.1% after the company said Wegovy cut the risk o...
- US stocks end lower as conflict between Israel and Iran adds cautionU.S. stocks declined on Tuesday amid escalating tensions in the Middle East, as the Israel-Iran conflict intensified and the U.S. military ...
- Lupin acquires 'Huminsulin' in India from Eli Lilly and CoLupin Ltd has acquired the anti-diabetic medicine Huminsulin in India from Eli Lilly to expand its diabetes portfolio. This move aims to pr...
- AstraZeneca to buy fusion for $2 billionThe deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when ...
- Novartis buys GSK's cancer drugs for $14.5 billion in a 3-way dealThe collaboration between the two will create a new world-leading consumer healthcare business with $10 billion in annual sales.
- Eli Lilly's to bet on original drugs to triple sales in India over next 5 yearsUnlike other foreign drugmakers, it plans to stay away from acquisition of local firms or branded generics to boost its market share.
- FDI cap in pharma will hurt global investor confidence: OPPIImposing restrictions on FDI in the pharmaceutical sector, in the wake of MNCs acquiring domestic firms would hurt overseas investment flow...
- SEC probes 9 transactions for insider trading violationsMany firms -- Pfizer, Merck, Wyeth, Eli Lilly and Abbott Laboratories, which are under investigation by SEC have significant presence in In...
- G2 acquires majority stake in domestic firmGlobal marketing services provider G2 Worldwide on Tuesday said it has acquired a majority stake in relationship management firm Chateux Ho...
- NPIL to invest Rs 300 cr in R&D unit: Domestic pharma major Nicholas Piramal India (NPIL) has decided to invest some Rs 250-300 crore in the next two years in its recently dem...
- Citi's Q1 profit slips to $5b on reorganisation costsCitigroup said on Monday its first-quarter profits fell 11% to $5.01 billion as the banking powerhouse set aside funds for a major belt-tig...
- Shasun to project R&D identityChennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company in t...
- Shasun to project R&D identityThe Chennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company ...
Load More
